## Cun Liu

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1531983/publications.pdf

Version: 2024-02-01

	361045	454577
1,160	20	30
citations	h-index	g-index
59	59	1557
docs citations	times ranked	citing authors
	citations 59	1,160 20 citations h-index  59 59

#	Article	IF	Citations
1	MicroRNA expression in cervical cancer: Novel diagnostic and prognostic biomarkers. Journal of Cellular Biochemistry, 2018, 119, 7080-7090.	1.2	82
2	Tumor Characterization in Breast Cancer Identifies Immune-Relevant Gene Signatures Associated With Prognosis. Frontiers in Genetics, 2019, 10, 1119.	1.1	64
3	Exploration of methylation-driven genes for monitoring and prognosis of patients with lung adenocarcinoma. Cancer Cell International, 2018, 18, 194.	1.8	59
4	The construction and analysis of ceRNA networks in invasive breast cancer: a study based on The Cancer Genome Atlas. Cancer Management and Research, 2019, Volume 11, 1-11.	0.9	49
5	A review of the biological activity and pharmacology of cryptotanshinone, an important active constituent in Danshen. Biomedicine and Pharmacotherapy, 2021, 137, 111332.	2.5	47
6	Meta-analysis of the association between the dietary inflammatory index (DII) and breast cancer risk. European Journal of Clinical Nutrition, 2019, 73, 509-517.	1.3	46
7	7-IncRNA Assessment Model for Monitoring and Prognosis of Breast Cancer Patients: Based on Cox Regression and Co-expression Analysis. Frontiers in Oncology, 2019, 9, 1348.	1.3	34
8	MicroRNAs associated with lung squamous cell carcinoma: New prognostic biomarkers and therapeutic targets. Journal of Cellular Biochemistry, 2019, 120, 18956-18966.	1.2	33
9	The Modulatory Properties of Astragalus membranaceus Treatment on Triple-Negative Breast Cancer: An Integrated Pharmacological Method. Frontiers in Pharmacology, 2019, 10, 1171.	1.6	32
10	Impact of endometriosis on risk of ovarian, endometrial and cervical cancers: a meta-analysis. Archives of Gynecology and Obstetrics, 2019, 299, 35-46.	0.8	32
11	SNP mutationâ€related genes in breast cancer for monitoring and prognosis of patients: A study based on the TCGA database. Cancer Medicine, 2019, 8, 2303-2312.	1.3	31
12	Prognostic value of aberrantly expressed methylation gene profiles in lung squamous cell carcinoma: A study based on The Cancer Genome Atlas. Journal of Cellular Physiology, 2019, 234, 6519-6528.	2.0	31
13	Integrative transcriptome data mining for identification of core IncRNAs in breast cancer. PeerJ, 2019, 7, e7821.	0.9	30
14	Tanshinone IIA: New Perspective on the Anti-Tumor Mechanism of A Traditional Natural Medicine. The American Journal of Chinese Medicine, 2022, 50, 209-239.	1.5	30
15	Four IncRNAs associated with breast cancer prognosis identified by coexpression network analysis. Journal of Cellular Physiology, 2019, 234, 14019-14030.	2.0	29
16	circRNAâ€associated ceRNA network construction reveals the circRNAs involved in the progression and prognosis of breast cancer. Journal of Cellular Physiology, 2020, 235, 3973-3983.	2.0	29
17	Tumor Mutation Burden and Immune Invasion Characteristics in Triple Negative Breast Cancer: Genome High-Throughput Data Analysis. Frontiers in Immunology, 2021, 12, 650491.	2.2	29
18	Role of Flavonoids in the Treatment of Iron Overload. Frontiers in Cell and Developmental Biology, 2021, 9, 685364.	1.8	29

#	ARTICLE	IF	Citations
19	Identifying the Antiproliferative Effect of Astragalus Polysaccharides on Breast Cancer: Coupling Network Pharmacology With Targetable Screening From the Cancer Genome Atlas. Frontiers in Oncology, 2019, 9, 368.	1.3	27
20	A Systems Biology-Based Approach to Uncovering Molecular Mechanisms Underlying Effects of Traditional Chinese Medicine Qingdai in Chronic Myelogenous Leukemia, Involving Integration of Network Pharmacology and Molecular Docking Technology. Medical Science Monitor, 2018, 24, 4305-4316.	0.5	25
21	Identification of the key pathways and genes involved in HER2-positive breast cancer with brain metastasis. Pathology Research and Practice, 2019, 215, 152475.	1.0	24
22	Cardiotoxicity of doxorubicin-based cancer treatment: What is the protective cognition that phytochemicals provide us?. Pharmacological Research, 2020, 160, 105062.	3.1	24
23	Natural Polysaccharides and Their Derivates: A Promising Natural Adjuvant for Tumor Immunotherapy. Frontiers in Pharmacology, 2021, 12, 621813.	1.6	22
24	Nanoformulations of Ursolic Acid: A Modern Natural Anticancer Molecule. Frontiers in Pharmacology, 2021, 12, 706121.	1.6	22
25	DNA methylationâ€based diagnostic and prognostic biomarkers of nonsmoking lung adenocarcinoma patients. Journal of Cellular Biochemistry, 2019, 120, 13520-13530.	1.2	21
26	Exploring the Mechanism of Danshen against Myelofibrosis by Network Pharmacology and Molecular Docking. Evidence-based Complementary and Alternative Medicine, 2018, 2018, 1-11.	0.5	18
27	Deciphering Key Pharmacological Pathways of Qingdai Acting on Chronic Myeloid Leukemia Using a Network Pharmacology-Based Strategy. Medical Science Monitor, 2018, 24, 5668-5688.	0.5	17
28	Target Analysis and Mechanism of Podophyllotoxin in the Treatment of Triple-Negative Breast Cancer. Frontiers in Pharmacology, 2020, 11, 1211.	1.6	17
29	Identification of IncRNAs associated with lung squamous cell carcinoma prognosis in the competitive endogenous RNA network. PeerJ, 2019, 7, e7727.	0.9	17
30	Identification of key candidate genes and miRNA‑mRNA target pairs in chronic lymphocytic leukemia by integrated bioinformatics analysis. Molecular Medicine Reports, 2019, 19, 362-374.	1.1	16
31	The effect of long noncoding RNAs HOX transcript antisense intergenic RNA singleâ€nucleotide polymorphisms on breast cancer, cervical cancer, and ovarian cancer susceptibility: A metaâ€analysis. Journal of Cellular Biochemistry, 2019, 120, 7056-7067.	1.2	16
32	Biomarker expression analysis in different age groups revealed age was a risk factor for breast cancer. Journal of Cellular Physiology, 2020, 235, 4268-4278.	2.0	14
33	Development of a risk scoring system for evaluating the prognosis of patients with Her2-positive breast cancer. Cancer Cell International, 2020, 20, 121.	1.8	14
34	Remodeling the Epigenetic Landscape of Cancerâ€"Application Potential of Flavonoids in the Prevention and Treatment of Cancer. Frontiers in Oncology, 2021, 11, 705903.	1.3	14
35	Research progress of phenolic compounds regulating <scp>IL</scp> â€6 to exert antitumor effects. Phytotherapy Research, 2021, 35, 6720-6734.	2.8	13

The association between statin use and endometrial cancer survival outcome. Medicine (United) Tj ETQq0.00 rgBT $_{0.4}^{10}$  Voverlock  $_{12}^{10}$  Tf 50 6  $_{0.4}^{10}$ 

#	Article	IF	Citations
37	Natural compounds: A new perspective on targeting polarization and infiltration of tumor-associated macrophages in lung cancer. Biomedicine and Pharmacotherapy, 2022, 151, 113096.	2.5	11
38	Comparative efficacy of different targeted therapies plus fulvestrant for advanced breast cancer following progression on prior endocrine therapy: a network meta-analysis. Cancer Management and Research, 2018, Volume 10, 5869-5880.	0.9	10
39	Identification of key candidate targets and pathways for the targeted treatment of leukemia stem cells of chronic myelogenous leukemia using bioinformatics analysis. Molecular Genetics & amp; Genomic Medicine, 2019, 7, e851.	0.6	10
40	A Novel Glycolysis-Related Four-mRNA Signature for Predicting the Survival of Patients With Breast Cancer. Frontiers in Genetics, 2021, 12, 606937.	1.1	10
41	Construction and Analysis of Competing Endogenous RNA Networks for Breast Cancer Based on TCGA Dataset. BioMed Research International, 2020, 2020, 1-10.	0.9	9
42	<p>Efficacy and safety of targeted therapy for metastatic HER2-positive breast cancer in the first-line treatment: a Bayesian network meta-analysis</p> . OncoTargets and Therapy, 2019, Volume 12, 959-974.	1.0	8
43	Protein–protein interaction networks and different clustering analysis in Burkitt's lymphoma. Hematology, 2018, 23, 391-398.	0.7	6
44	Efficacy and safety of de-escalation bone-modifying agents for cancer patients with bone metastases: a systematic review and meta-analysis. Cancer Management and Research, 2018, Volume 10, 3809-3823.	0.9	6
45	6-IncRNA Assessment Model for Monitoring and Prognosis of HER2-Positive Breast Cancer: Based on Transcriptome Data. Pathology and Oncology Research, 2021, 27, 609083.	0.9	6
46	An mRNA characterization model predicting survival in patients with invasive breast cancer based on The Cancer Genome Atlas database. Cancer Biomarkers, 2021, 30, 417-428.	0.8	5
47	Developing DNA methylationâ€based prognostic biomarkers of acute myeloid leukemia. Journal of Cellular Biochemistry, 2018, 119, 10041-10050.	1.2	4
48	Deciphering the mechanism of Indirubin and its derivatives in the inhibition of Imatinib resistance using a "drug target prediction-gene microarray analysis-protein network construction―strategy. BMC Complementary and Alternative Medicine, 2019, 19, 75.	3.7	4
49	Deciphering of Key Pharmacological Pathways of Poria Cocos Intervention in Breast Cancer Based on Integrated Pharmacological Method. Evidence-based Complementary and Alternative Medicine, 2020, 2020, 1-11.	0.5	4
50	Gene signatures of 6-methyladenine regulators in women with lung adenocarcinoma and development of a risk scoring system: a retrospective study using the cancer genome atlas database. Aging, 2021, 13, 3957-3968.	1.4	4
51	Identifying the Effect of Ursolic Acid Against Triple-Negative Breast Cancer: Coupling Network Pharmacology With Experiments Verification. Frontiers in Pharmacology, 2021, 12, 685773.	1.6	4
52	Acupuncture for Aromatase Inhibitor–Related Joint Pain Among Breast Cancer Patients. JAMA - Journal of the American Medical Association, 2018, 320, 2270.	3.8	3
53	Cryptotanshinone Is a Intervention for ER-Positive Breast Cancer: An Integrated Approach to the Study of Natural Product Intervention Mechanisms. Frontiers in Pharmacology, 2020, 11, 592109.	1.6	3
54	Determination of Genetic and Epigenetic Modifications-Related Prognostic Biomarkers of Breast Cancer: Genome High-Throughput Data Analysis. Journal of Oncology, 2021, 2021, 1-12.	0.6	3

#	Article	IF	CITATIONS
55	Analysis of the expression patterns and clinical relevance of m6A regulators in 33 cancer types. Future Oncology, 2022, 18, 565-577.	1.1	1
56	Letter to the editor: efficacy and safety of a combination of HER2-targeted agents as first-line treatment for metastatic HER2-positive breast cancer: a network meta-analysis. Expert Opinion on Drug Safety, 2018, 17, 1151-1152.	1.0	0